The Buck® MC (Modular Containment) Valve from GEA Pharma Systems Buck® offers inspired technology with a number of key additional features and benefits over the current generation of split butterfly valves, including:
• Unique passive-to-passive valve design with a centralised actuation collar.
• The passive valves are freely orientating reducing operator docking error.
• Modular Containment: The Buck® MC valve has 1-10 µg/m³ containment level as standard. The system can, however, easily be upgraded with the advanced air cleaning actuator to further improve containment levels to <1 µg/m³, allowing reduced investment today with flexibility for more potent products tomorrow.
• Simple operation: The need for vacuum clamping between the valve halves has been eliminated.
• Simple Maintenance: No lubrication of the disc parts is necessary and there are fewer component parts and more identical parts owing to the passive-to-passive design: this helps reduce spare part inventory.
• Clean In Place (CIP) or Clean Out of Place (COP) as standard.
• Robust docking: The new central actuator design overcomes potential misalignment from fabrication tolerances of the container and docking station.
The Buck® valves were supplied by S3 Process, GEA exclusive agent for the UK market. S3 Process is an agency whose philosophy is to work with leading edge process technologies that deliver real quality and cost benefits to its customers. The company also played a leading role in the design of the materials handling solution and the integration of the Buck® valves within the processing line. Mike Battrum, Aesica’s Head of Engineering said: “S3 came up with a highly technical, yet practical solution for the critical powder transfer operations, the most hazardous part of the project design. This included significant collaboration with other contractors and Aesica engineers in the project team.”
As the market for the contract manufacture of potent drugs continues to grow, Aesica believes that the investment in the new containment facility will enable it to significantly extend its formulation offering in this particular market. It is estimated that the new facility will be completed by June 2011 and once operational will enable Aesica to manufacture Schedule II controlled drugs such as opiates, as well as potent drugs typically classed as Safebridge category 3.
GEA Pharma Systems will be exhibiting a range of Buck valves at Interpack in Düsseldorf from 12 – 18 May on stand number F24, Hall 8a.
Learn more about Compression at Interpack 2011 www.gea-ps.com/interpack
Join GEAPharma @ Twitter; Facebook & YouTube
Where inspiration meets technology
Further editorial information from:
Steve Jordan - The Words Workshop Ltd.
26 Swanwick Lane, Milton Keynes, MK10 9LD
Tel: (44) (0) 1908 695500 Fax: (44) (0) 1908 690099
Email: steve@thewordsworkshop.co.uk
Web: http://www.thewordsworkshop.co.uk
All business enquiries to:
Michaela Renkert - Buck® Sales
GEA Pharma Systems AG
Tel: +41 61 936 3636
Email: Michaela.renkert@geagroup.com
Web: http://www.geapharmasystems.com
About GEA Process Engineering
GEA Process Engineering develops designs and markets production plants for the dairy, brewery, foods and chemical industry. With a turnover of more than EUR 1 billion and approx. 4,000 employees working in subsidiaries located in more than 40 countries, GEA Process Engineering is world leader of industrial process plants within the above industries. The head office of GEA Process Engineering is located in Denmark with more than 500 Danish employees. GEA Process Engineering is a division of GEA Group AG. GEA Group AG is an international group listed on the German MDAX. The head office of GEA Group AG is in Bochum, Germany. In 2007, the turnover of GEA was more than EUR 5 billion and GEA employed more than 19,500 employees.
